Prof. Hannelore Denys from UZ Ghent shared some intriguing findings from the oral abstract session on gynaecologic cancer. The KEYNOTE-826 phase 3 study on pembrolizumab + chemotherapy for first-line treatment of cervical cancer revealed promising overall survival outcomes. Furthermore, the RUBY trial’s secondary efficacy outcomes and patient-reported outcomes for primary advanced or recurrent endometrial cancer patients treated with dostarlimab plus carboplatin/paclitaxel were summarized. Prof. Denys concluded with encouraging results from the phase 3 DUO-O trial in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation.
With the educational support of:
